Rating Change
UBS analysts upgraded Medtronic plc (NYSE:MDT) from Neutral to Buy on July 28, 2026.
Rating Change UBS analysts upgraded Medtronic plc (NYSE:MDT) from Neutral to Buy on July 28, 2026. Market Context Medtronic plc operates in the Healthcare sector. The stock…

UBS analysts upgraded Medtronic plc (NYSE:MDT) from Neutral to Buy on July 28, 2026.
Medtronic plc operates in the Healthcare sector. The stock currently trades at $86.88 with a market capitalization of $127.9B. The stock has declined 12.2% over the past 52 weeks.
Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. UBS's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 28, 2026 | UBS | Buy | N/A |
| Jul 10, 2026 | TD Cowen | Buy | N/A |
| Jul 06, 2026 | Evercore ISI Group | Outperform | N/A |
| Jun 17, 2026 | Needham | Buy | N/A |
| Jun 05, 2026 | Bernstein | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View MDT Stock Page
A Buy rating from UBS reflects the analyst's outlook on Medtronic plc (NYSE:MDT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MDT forecast page.
Current market data
NYSE · MDT
$91.23
Up: +$1.26 · +1.40%
Live quote updated
Keep reading
analyst ·
sec_filing ·
earnings ·
institutional ·